Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
Korea OKs export of botulinum toxin developed by Huons Global
By 박한나Published : Oct. 11, 2016 - 17:41
[THE INVESTOR] South Korean pharmaceutical company Huons Global has been granted approval from the health authorities to export its botulinum toxin, the firm said on Oct. 11.
The move came after the Huons’ newly developed drug HU-014JU, which is designed to help smooth out forehead frown lines, got the green light from the Ministry of Food and Drug Safety for its first and second clinical trials in August.
“The product is set to enter the domestic market in 2018. We will push ahead with plans to get global approvals,” said Kim Wan-seop, senior executive at Huons Global.
The drug maker will also move forward with the treatment to win approval from the US Food and Drug Administration for its clinical trials next year.
Shares in the KOSDAQ-listed firm climbed 7.47 percent to close at 48,200 won.
By Park Han-na (hnpark@heraldcorp.com)
The move came after the Huons’ newly developed drug HU-014JU, which is designed to help smooth out forehead frown lines, got the green light from the Ministry of Food and Drug Safety for its first and second clinical trials in August.
“The product is set to enter the domestic market in 2018. We will push ahead with plans to get global approvals,” said Kim Wan-seop, senior executive at Huons Global.
The drug maker will also move forward with the treatment to win approval from the US Food and Drug Administration for its clinical trials next year.
Shares in the KOSDAQ-listed firm climbed 7.47 percent to close at 48,200 won.
By Park Han-na (hnpark@heraldcorp.com)
